NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
Clinical Trials
91 trialsNCT04398680 2025-12-04
DREAMM 13
GlaxoSmithKline
Phase 1 Withdrawn
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT04784221 2025-09-17
NANOPRO
Centre Francois Baclesse
Phase 2 Withdrawn
NCT03560908 2025-05-01
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Withdrawn
NCT05900908 2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4 Withdrawn
NCT04791228 2025-01-01
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Children's National Research Institute
Phase 2 Withdrawn
NCT06050512 2024-11-19
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
University of Pittsburgh
Phase 1/2 Withdrawn
NCT06099418 2024-09-20
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
Nykode Therapeutics ASA
Phase 2 Withdrawn
NCT03925675 2024-09-03
18F-Fluciclovine PET and Multiparametric MR Imaging
Loma Linda University
Phase 2 Withdrawn
NCT06372574 2024-09-03
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
Genentech, Inc.
Phase 1 Withdrawn
NCT05622591 2024-08-07
Pediatric AML
Elucida Oncology
Phase 1 Withdrawn
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT06232707 2024-05-31
ALUMMINATE
Celgene
Phase 3 Withdrawn
NCT05966233 2024-05-21
FIL_POLARDHAP
Fondazione Italiana Linfomi - ETS
Phase 2 Withdrawn
NCT05367401 2024-04-11
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis
Phase 1/2 Withdrawn
NCT04864522 2023-11-21
MM FPBMC
University of Virginia
Phase 1/2 Withdrawn
NCT05647512 2023-11-18
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
LaNova Medicines Limited
Phase 1/2 Withdrawn
NCT05918250 2023-08-18
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
ModernaTX, Inc.
Phase 1 Withdrawn
NCT05512182 2023-06-15
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
Yonsei University
Phase 2 Withdrawn
NCT03999658 2023-05-01
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
Phase 2 Withdrawn
NCT05330377 2023-04-25
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
University of Kentucky
Phase 1 Withdrawn
NCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT05408026 2023-01-27
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Alliance Foundation Trials, LLC.
Phase 1/2 Withdrawn
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT05060276 2023-01-26
Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
Phase 1 Withdrawn
NCT04796922 2022-07-18
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Incyte Corporation
Phase 3 Withdrawn
NCT05279859 2022-06-15
HERKULES-4
Erasca, Inc.
Phase 1/2 Withdrawn
NCT05170789 2022-05-04
ESdRRMM
Tulane University
Phase 2 Withdrawn
NCT04456023 2022-03-02
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
Novartis
Phase 2 Withdrawn
NCT04826029 2021-12-10
QUALOV
Assistance Publique - Hôpitaux de Paris
Phase NA Withdrawn
NCT03873025 2021-08-17
PLACARD
University College, London
Phase 1/2 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT03605589 2021-04-01
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Withdrawn
NCT03361319 2020-11-24
N3
Royal Marsden NHS Foundation Trust
Phase 1/2 Withdrawn
NCT04561817 2020-10-06
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn
NCT03121079 2020-09-23
Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation
Peking University People's Hospital
Phase NA Withdrawn
NCT03617484 2020-06-22
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT02713984 2020-03-19
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Southwest Hospital, China
Phase 1/2 Withdrawn
NCT04279938 2020-02-21
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
Royal Marsden NHS Foundation Trust
Phase 1 Withdrawn
NCT02800889 2020-01-29
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
CTI BioPharma
Phase 1 Withdrawn
NCT00129753 2018-11-08
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03207334 2018-10-22
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
University of Florida
Phase 2 Withdrawn
NCT02986451 2018-08-14
Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
Sun Yat-sen University
Phase 2 Withdrawn
NCT02780011 2018-07-27
AD3LE
The Methodist Hospital Research Institute
Phase 1 Withdrawn
NCT02718755 2018-06-26
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02985333 2018-05-14
Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
Phase 2 Withdrawn
NCT02204020 2018-03-30
UPCI 13-165
University of Pittsburgh
Phase 2 Withdrawn
NCT02269579 2018-03-14
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Jazz Pharmaceuticals
Phase 2 Withdrawn
NCT02962804 2018-03-05
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
University of Kansas Medical Center
Phase 2 Withdrawn